Alnylam Pharmaceuticals | ALNY - Interest Income

Stock Price
455.63
Daily Change
3.63 0.80%
Monthly
4.74%
Yearly
79.98%
Q3 Forecast
448.25

Alnylam Pharmaceuticals reported $27.49M in Interest Income for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 4.57B
Cash and Equivalent USD 1.11B
Cost of Sales USD 142.95M
Current Assets USD 3.64B
Current Liabilities USD 1.3B
Debt USD 1.3B
EBIT USD 4.89M
EBITDA USD 18.83M
Employees 2.23K
EPS Earnings Per Share USD 0.32
Equity Capital and Reserves USD 250.59M
Gross Profit on Sales USD 630.74M
Interest Expense on Debt USD 40.25M
Interest Income USD 27.49M
Loan Capital USD 1.03B
Market Capitalization USD 59.08B
Net Income USD -66.28M
Operating Expenses USD 789.89M
Operating Profit USD -16.2M
Ordinary Share Capital USD 130.98M
Pre-Tax Profit USD -35.36M
Sales Revenues USD 773.69M
Selling and Administration Expenses USD 323.31M
Stock USD 71.69M
Trade Creditors USD 102.39M
Trade Debtors USD 567.11M

Interest Income Change Date
Acadia Pharmaceuticals USD 7.24M 658K Jun/2025
Agios Pharmaceuticals USD 14.51M 1.57M Jun/2025
Alnylam Pharmaceuticals USD 27.49M 1.19M Jun/2025
Arrowhead Research USD 9.62M 2.01M Mar/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Incyte USD 25.14M 2.21M Jun/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Moderna USD 81M 9M Jun/2025
Regeneron Pharmaceuticals USD 174.8M 1.3M Jun/2025
Sanofi EUR 76M 77M Jun/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Takeda JPY 73.76B 81.93B Jun/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025
Xencor USD 7.25M 290K Jun/2025